DK0615751T3 - Anvendelse af tachykininantagonister til behandling af emesis - Google Patents

Anvendelse af tachykininantagonister til behandling af emesis

Info

Publication number
DK0615751T3
DK0615751T3 DK94200691T DK94200691T DK0615751T3 DK 0615751 T3 DK0615751 T3 DK 0615751T3 DK 94200691 T DK94200691 T DK 94200691T DK 94200691 T DK94200691 T DK 94200691T DK 0615751 T3 DK0615751 T3 DK 0615751T3
Authority
DK
Denmark
Prior art keywords
tachykinin antagonists
antagonists
treat emesis
emesis
treat
Prior art date
Application number
DK94200691T
Other languages
Danish (da)
English (en)
Inventor
Russell Michael Hagan
Keith Thomas Bunce
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of DK0615751T3 publication Critical patent/DK0615751T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrane Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Indole Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK94200691T 1993-03-19 1994-03-17 Anvendelse af tachykininantagonister til behandling af emesis DK0615751T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB939305718A GB9305718D0 (en) 1993-03-19 1993-03-19 Medicaments

Publications (1)

Publication Number Publication Date
DK0615751T3 true DK0615751T3 (da) 2002-02-18

Family

ID=10732372

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94200691T DK0615751T3 (da) 1993-03-19 1994-03-17 Anvendelse af tachykininantagonister til behandling af emesis

Country Status (9)

Country Link
US (2) US5547964A (de)
EP (1) EP0615751B1 (de)
JP (2) JPH072658A (de)
AT (1) ATE209909T1 (de)
DE (1) DE69429299T2 (de)
DK (1) DK0615751T3 (de)
ES (1) ES2164684T3 (de)
GB (1) GB9305718D0 (de)
PT (1) PT615751E (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0916346A3 (de) 1991-09-20 2000-12-06 Glaxo Group Limited NK-1 Rezeptor Antagonisten und 5HT3 Rezeptor Antagonisten zur Behandlung von Emesis
US6048859A (en) 1992-06-29 2000-04-11 Merck & Co., Inc. Morpholine and thiomorpholine tachykinin receptor antagonists
DK0700384T3 (da) * 1993-05-28 1997-12-08 Pfizer fremgangsmåde til fremstilling og opløsning af 2-phenyl-3-aminopiperidin
US5393762A (en) * 1993-06-04 1995-02-28 Pfizer Inc. Pharmaceutical agents for treatment of emesis
TW432061B (en) * 1994-08-09 2001-05-01 Pfizer Res & Dev Lactams
US5576317A (en) * 1994-12-09 1996-11-19 Pfizer Inc. NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of emesis
GB9426102D0 (en) 1994-12-23 1995-02-22 Merck Sharp & Dohme Pharmacuetical compositions
GB9513972D0 (en) * 1995-07-08 1995-09-06 Merck Sharp & Dohme Pharmaceutical compositions
TW458774B (en) 1995-10-20 2001-10-11 Pfizer Antiemetic pharmaceutical compositions
ATE223896T1 (de) * 1995-12-21 2002-09-15 Pfizer 3-((5-substituierte benzyl)amino)-2- phenylpiperidine als substance-p-antagonisten
JP2000514047A (ja) * 1996-06-26 2000-10-24 ワーナー―ランバート・コンパニー 催吐の処置用医薬の製造のためのタキキニンアンタゴニストの使用
US6362371B1 (en) * 1998-06-08 2002-03-26 Advanced Medicine, Inc. β2- adrenergic receptor agonists
EP1145714A4 (de) * 1998-11-27 2004-12-15 Takeda Chemical Industries Ltd Arzneimittel
NZ501211A (en) * 1999-01-29 2001-10-26 Pfizer Prod Inc Pharmaceutical composition comprising macrolide antibiotic like erythromycin and a Substance P antagonist, and method for treating cancer, bacterial and protozoal infection in non-humans
IL142810A0 (en) * 2000-05-03 2002-03-10 Pfizer Prod Inc Pharmaceutical uses for fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles
EP1205855A3 (de) * 2000-11-10 2006-01-25 Masae Yanagi Verfahren, System und Vorrichtung zum Verwalten von Daten, Datenhandlungsgerät, Rechnerprogramm und Speichermedium
CA2567342A1 (en) * 2004-06-08 2005-12-22 Travis T. Wager Aza-bicyclo[3.1.0]hex-1-yl derivatives active as nk1 antagonists
CN101190330A (zh) 2006-11-30 2008-06-04 深圳市鼎兴生物医药技术开发有限公司 胆碱酯酶在拮抗速激肽药物中的应用
KR20090112722A (ko) 2007-01-24 2009-10-28 글락소 그룹 리미티드 3,5-디아미노-6-(2,3-디클로로페닐)-1,2,4-트리아진 또는 ｒ(-)-2,4-디아미노-5-(2,3-디클로로페닐)-6-플루오로메틸 피리미딘 및 ｎｋ1을 포함하는 제약 조성물
JP5860399B2 (ja) * 2009-08-14 2016-02-16 オプコ ヘルス， インコーポレイテッド ニューロキニン−１アンタゴニストの静脈内用製剤
WO2020019247A1 (en) * 2018-07-26 2020-01-30 Xw Laboratories, Inc. Compounds as neurokinin-1 receptor antagonists and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4048058A (en) * 1975-08-13 1977-09-13 Standard Oil Company (Indiana) Methods to be used in reforming processes employing multi-metallic catalysts
US4066772A (en) * 1975-07-21 1978-01-03 Janssen Pharmaceutica N.V. 1,3-Dihydro-1-[3-(1-piperidinyl)propyl]-2H-benzimidazol-2-ones and related compounds
FR2610323B1 (fr) * 1987-02-04 1989-06-23 Delalande Sa Enantiomeres de configuration absolue s de derives amide de l'amino-3 quinuclidine, leur procede de preparation et leur application en therapeutique
FR2654725B1 (fr) * 1989-11-23 1992-02-14 Rhone Poulenc Sante Nouveaux derives de l'isoindolone, leur preparation et les compositions pharmaceutiques qui les contiennent.
US5232929A (en) * 1990-11-28 1993-08-03 Pfizer Inc. 3-aminopiperidine derivatives and related nitrogen containing heterocycles and pharmaceutical compositions and use
KR0145432B1 (ko) * 1991-03-26 1998-07-15 알렌 제이. 스피겔 치환된 피페리딘의 입체선택적 제조 방법
DK0589924T3 (da) * 1991-06-20 1996-09-30 Pfizer Fluoralkoxybenzylaminoderivater af nitrogenholdige heterocyclusser
EP0522808A3 (de) * 1991-07-05 1993-01-27 MERCK SHARP & DOHME LTD. Aromatische Verbindungen, diese enthaltende pharmazeutische Zusammensetzungen und ihre therapeutische Anwendung
EP0916346A3 (de) * 1991-09-20 2000-12-06 Glaxo Group Limited NK-1 Rezeptor Antagonisten und 5HT3 Rezeptor Antagonisten zur Behandlung von Emesis
US5393762A (en) * 1993-06-04 1995-02-28 Pfizer Inc. Pharmaceutical agents for treatment of emesis

Also Published As

Publication number Publication date
PT615751E (pt) 2002-04-29
DE69429299D1 (de) 2002-01-17
JPH072658A (ja) 1995-01-06
EP0615751B1 (de) 2001-12-05
US6329394B1 (en) 2001-12-11
ATE209909T1 (de) 2001-12-15
EP0615751A1 (de) 1994-09-21
GB9305718D0 (en) 1993-05-05
ES2164684T3 (es) 2002-03-01
JP2000191522A (ja) 2000-07-11
US5547964A (en) 1996-08-20
DE69429299T2 (de) 2002-10-17

Similar Documents

Publication Publication Date Title
DK0615751T3 (da) Anvendelse af tachykininantagonister til behandling af emesis
DK0627221T3 (da) Substans P antagonister til behandling af emesis
FI935585A0 (fi) Pyrrolopyrimidiner
DE60133029D1 (de) Mittel zur prävention oder behandlung von psoriasi
TR200202323T2 (tr) Akut akciğer harabiyeti ve fibrozitinin alfavß6 antagonistleriyle tedavisi
MX9205639A (es) Composiciones y tejidos de polimeros tratados con las mismas.
DE69019363D1 (de) Desinfizierende zusammensetzung und desinfektionsverfahren.
ES2058346T3 (es) Compuestos piperidinilicos 1,4-disustituidos.
DE69735482D1 (de) Spiro-azacyclische derivate, deren herstellung und verwendung als tachykinin-antagonisten
ITTO930547A0 (it) Procedimento e macchina per sterilizzare o disinfettare i rifiuti.
DE69531356D1 (de) Kristallisierung von levobupivacaine und deren analogen
KR100292396B1 (de)
DE69832722D1 (de) L-threonat-eisen, pharmazeutische zusammensetzung und verwendung zur verbesserung und behandlung von anämie bei menschen
DE59408191D1 (de) Cyclische Verbindungen und ihre Anwendung als Riechstoffe
ES2044100T3 (es) Ciertas combinaciones de antagonistas del "paf" y antihistaminicos y metodos.
ATE359808T1 (de) Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma
DK0583281T3 (da) Modgift - immunsera
ES2150418T3 (es) Composiciones farmaceuticas que comprenden calcitonina.
ATE373475T1 (de) Carbamate von 2-heterozyklischen 1,2-ethandiolen
TR200101476T2 (tr) N-ikameli azabisikloaklan türevlerinin merkezi sinir sistemi bozukluklarının tedavisinde kullanılması
SE9403861D0 (sv) Novel medicinal use
DE59407576D1 (de) Verwendung von Etofibrat und pharmazeutische Zusammensetzungen, enthaltend Etofibrat, zur Behandlung der diabetischen Angio- und Retinopathie
ES2141923T3 (es) Uso hipocolesterolemico, antiaterosclerotico e hipotrigliceridemico de derivados aminoacetilmercapto.
TR200000916T2 (tr) İkameli piperidin türevleri.
DK1133297T3 (da) Ny terapeutisk anvendelse af 1,6-dimethyl-8beta-hydroxymethyl-10alpha-methoxyergolin